

IN THE DRAWINGS:

A copy of Fig. 1 has been supplied with the amendment (the addition of SEQ ID NO:) indicated in red. This correction will be made formally when formal figures are filed at a later date.

IN THE ABSTRACT:

On page 27, please delete the Abstract of the Disclosure and insert the following replacement Abstract of the Disclosure. Pursuant to 37 C.F.R. § 1.121, the following is a clean copy of the Abstract of the Disclosure. A marked-up copy of the Abstract of the Disclosure is attached on a separate sheet.

The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPN
ANS (SEQ ID NO: 1). Hybrid molecules comprise for instance a cationic peptide with an antimicrobial action and/or a peptide fragment of ubiquicidine and/or a derivative thereof and one or more effector molecules.